BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25795717)

  • 1. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
    Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
    Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
    Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
    N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
    Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
    Stanworth SJ; Estcourt LJ; Llewelyn CA; Murphy MF; Wood EM;
    Transfusion; 2014 Oct; 54(10):2385-93. PubMed ID: 24724863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
    Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
    Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L.
    Nevo S; Fuller AK; Zahurak ML; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 Sep; 47(9):1700-9. PubMed ID: 17725737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks.
    Cornelissen LL; Caram-Deelder C; Fustolo-Gunnink SF; Groenwold RHH; Stanworth SJ; Zwaginga JJ; van der Bom JG
    Transfusion; 2021 Sep; 61(9):2578-2587. PubMed ID: 34263930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth SJ; Hyde C; Brunskill S; Murphy MF
    Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting.
    Ypma PF; Kerkhoffs JL; van Hilten JA; Middelburg RA; Coccoris M; Zwaginga JJ; Beckers EM; Fijnheer R; van der Meer PF; Brand A
    Transfus Med; 2012 Dec; 22(6):426-31. PubMed ID: 23036067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New thoughts on the correct dosing of prophylactic platelet transfusions to prevent bleeding.
    Slichter SJ
    Curr Opin Hematol; 2011 Nov; 18(6):427-35. PubMed ID: 21946073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How low can you go: What is the safe threshold for platelet transfusions in patients with hematologic malignancy in sub-Saharan Africa.
    Ddungu H; Krantz EM; Kajja I; Naluzze S; Nabbanja H; Nalubwama F; Phipps W; Orem J; Kiwanuka N; Wald A
    PLoS One; 2019; 14(2):e0211648. PubMed ID: 30726290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
    Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D
    Transfusion; 2004 Dec; 44(12):1711-9. PubMed ID: 15584985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
    Vinholt PJ; Alnor A; Nybo M; Hvas AM
    Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger.
    Zumberg MS; del Rosario ML; Nejame CF; Pollock BH; Garzarella L; Kao KJ; Lottenberg R; Wingard JR
    Biol Blood Marrow Transplant; 2002; 8(10):569-76. PubMed ID: 12434952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic platelet transfusions: should they be a treatment of the past?
    Zeller MP; Al-Habsi KS; Heddle NM
    Curr Opin Hematol; 2014 Nov; 21(6):521-7. PubMed ID: 25203535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
    Stanworth SJ; Dyer C; Casbard A; Murphy MF
    Vox Sang; 2006 Jul; 91(1):63-9. PubMed ID: 16756603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.